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 Abstract 
The carbon monoxide (CO) releasing properties of a series of Rhenium(II)-based complexes of 
general formula cis-trans-[ReII(CO)2Br2L2]n  and cis-trans-[ReII(CO)2Br2N∩N] (where L = monodentate  
and N∩N = bidentate ligand) are reported. Complexes evaluated in this study were obtained from direct 
ligand substitution reactions of the cis-[ReII(CO)2Br4]2- synthon (2) recently described.1 All molecules 
have been fully characterized. The solid state structures of the cis-trans-[ReII(CO)2Br2L2] (with L = N-
methylimidazole (3), benzimidazole (4) and 4-picoline (5)) and the cis-trans-[ReII(CO)2Br2N∩N] (with 
N∩N = 4,4'-dimedthyl-2,2'-bipyridine (8) and 2,2 -dipyridylamine (11)) adducts are presented. The 
release of CO from the cis-trans-[ReII(CO)2Br2L2]n complexes was assessed spectrophotometrically by 
measuring the conversion of deoxymyoglobin (Mb) to carbonmonoxy myoglobin (MbCO). Only 
compounds bearing monodentate ligands were found to liberate CO. The rate of CO release was found 
to be pH-dependent with half lives (t1/2) under physiological conditions (25 °C, 0.1 M phosphate buffer, 
pH 7.4) varying from ca. 6 to 43 min. At lower pH values the time required to fully saturate Mb with 
CO liberated from the metal complexes gradually decreased. Complex 2 and the cis-trans-
[ReII(CO)2Br2(Im)2] adduct (with Im = imidazole (6)) show a protective action against “ischemia-
reperfusion” stress of neonatal rat ventricular cardiomyocytes (NRCs) in culture.  
 
 
Introduction. 
In recent years carbon monoxide (CO) has been acknowledged as a fundamental (small-molecule) 
gaseous messenger in humans.2 The endogenous production of CO is associated with the heme 
metabolic pathway and the action of a family of enzymes known as heme oxygenases (HO’s).2 HO’s 
catalyze the oxidation of heme to biliverdin resulting in the production of free iron and CO (scheme 1). 
The distribution of HO’s is strictly tissue specific and HO-derived CO carry on a number of local 
physiological functions. Carbon monoxide acts as a signaling molecule in cytoprotective signaling 
cascade activated by various stress stimuli.3, 4 Similar to nitric monoxide, it plays a fundamental role in 
the circulatory system by improving vasorelaxation and cardiac blood supply.5-9 CO also appears to 
influence neurotransmission in the hypothalamic-pituary-adrenal axis like NO10-12 and there is evidence 
that CO might influence our circadian rhythm13 (the 24-hour cycle in the biochemical, physiological or 
behavioural processes) by interacting with NPAS2 (the human “clock” protein).14  Furthermore, carbon 
monoxide was reported to attenuate arteriosclerotic lesions associated with chronic graft rejection.15 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Heme-catalyzed endogenous production of CO. 
As the importance of CO is increasingly recognized, there is a growing interest in the 
pharmacological and medicinal applications of carbon monoxide.16-22 Direct inhalation of CO has been 
viewed as a novel therapeutic approach but reports on tolerance to CO exposure are contradictory.4, 23, 24 
There is a very delicate balance between CO induced tissue hypoxia and therapeutic effects. 
Furthermore, the direct use of the gaseous molecule poses problems associated with its safe handling 
and delivery to specific target sites in a controlled and measurable fashion. An alternative approach to 
the administration of carbon monoxide is the use of CO-releasing molecules (CO-RMs). An obvious 
choice for CO-RMs are transition metal carbonyl complexes with one or more CO ligands.  
Several complexes have been evaluated to date,19, 25-31 but the pioneering work of Motterlini and 
Mann has resulted in the discovery of the fac-[RuCl(glycinato)(CO)3] complex (CORM-3) as the most 
promising compound for the CO release in vivo.5, 32-34 The chemistry and therapeutic effects of CORM-3 
are well documented. The Ru complex releases 1 mol of CO within 10 min after dissolving in water and 
it has been shown that CORM-3 significantly reduces blood pressure in vivo and relaxes precontracted 
aortic rings in vitro. 5, 32-34  The cardioprotective functions of CORM-3 have also been described.5 
   We have recently reported that the one electron reduction of cis-[ReIII(CO)2Br4]- (1) results in the 
stable ReII synthon cis-[ReII(CO)2Br4]2- (2).1 While the chemistry of 1 is largely underdeveloped, we 
have demonstrated that 2 reacts well with pyridine-type ligands.1 The chemistry of rhenium complexes 
in the oxidation state +II (d5 configuration) is rare if compared to the other oxidation states of this metal 
ion. However, the related paramagnetism together with the open shell electronic configuration makes 
such complexes interesting for various applications in medicine, magnetochemistry or catalysis. Here 
we show that 2 and several other [ReII(CO)2Br2L2] complexes (where L = monodentate ligand) act as 
CO-releasing molecules and that under physiologically relevant conditions the rate of CO release is 
comparable to that of CORM-3. The complexes presented in this study represent a first example of 
metal-based CO-RMs in which the central metal ion is not found in a d6, d8 or d10 configuration. In our 
view, the open shell d5 configuration of the Re system herein described represents an advantage over the 
more robust d6, d8 or d10 systems for which physical stimuli (e.g. UV radiation) are often needed in order 
to elicit dissociation of carbon monoxide from the metal core.19, 25, 26, 30, 31, 35, 36 We further show that 
selected cis-trans-[ReII(CO)2Br2L2]n complexes induce a protective action against “ischemia-
reperfusion” stress of neonatal rat ventricular cardiomyocytes (NRCs) in culture. 
 
Experimental Section 
Chemicals and solvents were purchased from standard sources. Anhydrous dimethoxyethane (DME) 
was purchased from Aldrich and degassed prior to use. All other solvents were distilled and degassed 
prior to use. (NEt4)2[ReBr3(CO)3], compounds 1, 2, 6, 7, 12 and 13  were synthesized as previously 
described.1, 37, 38 All other complexes were synthesized under nitrogen with standard techniques. 
Elemental analyses (EA) were performed on a Leco CHNS-932 elemental analyser. IR spectra were 
recorded in a PerkinElmer Spectrum BX FT-IR spectrometer. UV-visible spectra were recorded on a 
Varian Carry 50 Scan spectrometer. Cyclic voltammetry experiments were performed and data analyzed 
with a Metrohm 757 VA Computertrace package version 2.0. For the determination of rhenium uptake 
by the cells, cultured NRCs (106 cells/petri-dish, 5 days after isolation) were incubated for 5, 10, 30, 60 
and 120 min in the presence of 30 µM of the rhenium complexes. The medium was collected for 
analysis and the cells were triple-washed free from the extracellular ReII with phosphate buffer and wet-
burned in 200 µl concentrated metal free (TraceSelect) HNO3 (Fluka). Cell culture medium samples 
were acidified with 0.2 M HNO3. The amount of rhenium in the cells and the medium samples were 
analysed with flame atomic absorption spectroscopy (F-AAS) using an AA240FS spectrometer (Varian 
AG, Zug, Switzerland). Crystallographic data were collected at 183(2) K with Mo Kα radiation (λ = 
0.7107 Å) that was monochromated with help of a graphite on an Oxford Diffraction Xcalibur system 
with a Ruby detector. Suitable crystals were covered with oil (Infineum V8512), mounted on top of a 
glass fiber and immediately transferred to the diffractometer. The program suite CrysAlisPro was used 
for data collection, semi-empirical absorption correction and data reduction.39 Structures were solved 
with direct methods using SIR9740 and were refined by full-matrix least-squares methods on F2 with 
SHELXL-97.41 The structures were checked for higher symmetry with help of the program Platon.42 
CCDC 749656 – 749660 contain the supplementary crystallographic data for this paper. These data can 
be obtained from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
Detection of CO release using the myoglobin assay. 
The release of CO from the cis-trans-[ReII(CO)2Br2L2]n complexes was assessed 
spectrophotometrically by measuring the conversion of deoxymyoglobin (Mb) to carbonmonoxy 
myoglobin (MbCO) as previously reported.5, 19, 21 A small aliquot of a freshly prepared concentrated 
solution of the selected ReII complex (in methanol 2, in DMSO all other complexes) was added to 1 ml 
of the Mb solution in phosphate buffer prepared at different pHs (7.4, 6.3 and 5.8; final concentrations: 
30 μM for ReII complex and Mb). Changes in the Mb spectra were recorded over time at 25 °C. The 
methanol or DMSO content of the solution never exceeded 0.5%. The amount of MbCO formed was 
determined by measuring the absorbance at 540 nm (extinction coefficient = 15.4 M–1 cm–1). The MbCO 
concentration was plotted over time and directly related to the equivalents of CO released from the 
compounds. The half-life of CO release from the ReII complexes at different pH’s was then estimated 
from the graphs. Control experiments were run under identical conditions but without addition of the 
metal complexes. All manipulations were performed under a pure N2 atmosphere in a wet box. 
In Vitro Model of “Ischemia-Reperfusion” Stress of Cardiomyocyte.   
Animal keeping, breeding and experimentation were reviewed, approved, and carried out in 
accordance with the Swiss animal protection laws and institutional guidelines. Neonatal rat ventricular 
cardiomyocytes (NRCs) were isolated from Wistar rat pups (postnatal day 3-4) as described elsewhere.43 
The cells were kept in culture for 4 days and then used for experiments. The culture medium was 
exchanges for a glucose-free medium titrated to pH 6.0 and the cells were placed into a hypoxic 
incubator and exposed to 1% O2, 5% CO2 and 94% N2 for 16 h to simulate ischemic conditions. 
Thereafter, reperfusion was simulated by replacing the medium for one containing 5 mM glucose 
titrated to pH 7.4 and oxygen concentration in the incubator was increased to 20%. This protocol will be 
referred to as “ischemia-reperfusion” stress. The tested compounds were freshly dissolved in DMSO (30 
mM stock solutions) before the experiment and added to obtain a final concentration of 30 µM 
immediately after the incubation medium was been changed (at the “onset of reperfusion”). A 
corresponding amount of DMSO was added to the control non-treated cells. Following 12 h of 
“reperfusion” the cells were stained with a mixture of propidium iodide (PI, 0.5 µg/ml) and Hoechst 
33342 reagent (0.1 µg/ml) in phosphate buffer for 10 min and the number of Hoechst 33342- and PI-
positive nuclei was assessed using fluorescent microscope equipped with DAPI (409 nm excitation /450 
nm emission) and Cy3 (550 nm excitation /570 nm emission) filters and CCD chamber. The images 
obtained for the PI and Hoechst 33342 fluorescent signals were then analysed using MCID image 
analysis software pack. The total number of cells (Hoechst 33342-positive) and the total number of dead 
cells (PI-positive) was obtained. NRCs were plated (~ 1 million cells per dish) and grown in petri dishes 
of 4.5 cm2 area. After 4 days most cells were confluent and contracted rhythmically in concert. Counted 
were 5 areas in each dish at pre-fixed positions amounting to a total of 400 cells counted per dish. The 
statistical analysis was performed using normality test with the following non-paired Student’s test 
using GraphPad Prism 5 (GraphPad Software).  
Synthesis of [ReBr2(CO)2(MeIm)2]  (3). 100 mg of 2 (0.122 mmol) were suspended in 15 ml of DME 
and 32 mg of N-methylimidazole (MeIm, 3 eq.) were added. The mixture was heated to 60 °C for 3.5 h 
and stopped when the red suspension had become a yellow solution and a yellow precipitate had 
formed. The mixture was filtered while still hot. A bright yellow solid of 3 was collected, dried in vacuo 
and recrystallized from a CH2Cl2/hexane mixture giving dark red crystals. Yield: 49 mg, 71%. Anal. 
Calc. for C10H12Br2N4O2Re (566.2): C 21.21%, H 2.14%, N 9.89%. Found: C 21.89%, H 2.32%, N 
9.64%. I.r. (solid state, KBr, cm-1): νC O 1982, 1825. Single crystals suitable for x-ray diffraction were 
grown by slow diffusion of hexane into a CH2Cl2 solution of the compound. 
Synthesis of [ReBr2(CO)2(BzIm)2]  (4). 100 mg of 2 (0.122 mmol) were suspended in 15 ml of DME 
and 46 mg of benzimidazole (BzIm, 3 eq.) were added. The mixture was heated to 60 °C for 3.5 h and 
stopped when the red suspension had become a yellow solution and a yellow precipitate had formed. 
The mixture was filtered while still hot. A bright yellow solid of 4 was collected and dried in vacuo. The 
crude product was purified by loading a CH3OH solution of 4 onto a chromatofix C18 filter. This was 
washed with a 15% CH3OH solution in water and then extracted with CH3OH. Yield: 39 mg, 50%. 
Anal. Calc. for C16H12Br2N4O2Re (638.3): C 30.11%, H 1.89%, N 8.78%. Found: C 29.99 %, H 1.82%, 
N 8.47%. I.r. (solid state, KBr, cm-1): νC O 1992, 1833. Single crystals suitable for x-ray diffraction were 
grown by slow diffusion of hexane into a CH2Cl2 solution of the compound giving dark red crystals. 
Synthesis of [ReBr2(CO)2(4-pic)2]  (5). 100 mg of 2 (0.122 mmol) were suspended in 10 ml of DME 
and ca. 10 eq. 4-methylpyridine (4-pic, 100 µl) were added. After stirring overnight, a brownish 
precipitate was filtered off and dried in vacuo. The crude product was recrystallized from a 
CH2Cl2/hexane mixture giving dark red crystals of 5 which were found suitable for x-ray diffraction. 
Yield: 50 mg, 70%. Anal. Calc. for C14H14Br2N2O2Re (588.3): C 28.58%, H 2.40%, N 4.76%. Found: C 
28.39%, H 2.69%, N 4.88%. I.r. (solid state, KBr, cm-1): νC O 1992, 1830. 
Synthesis of [ReBr2(CO)2(4,4 -Mebipy)] (8). 100 mg of 2 (0.122 mmol) were suspended in 15 ml 
of DME and 28 mg of 4,4'-dimedthyl-2,2’-bipyridine (4,4'-Mebipy, 1.25 eq.) were added. The 
suspension was heated to 60 °C for 3.5 h and stopped when the red suspension had become a deep red 
solution. The mixture was allowed to cool to room temperature (RT) and then filtered. The dark red 
solution was dried in vacuo leaving 8 as a dark red solid. Yield: 70 mg, quantitative. Anal. Calc. for 
C14H12Br2N2O2Re (586.3): C 28.68%, H 2.04%, N 4.78%. Found: C 29.04%, H 2.52%, N 4.23%. I.r. 
(solid state, KBr, cm-1): νC O 1996, 1813. Single crystals suitable for x-ray diffraction were grown by 
slow diffusion of hexane into a CH2Cl2 solution of the compound giving dark red crystals. 
Synthesis of [ReBr2(CO)2(phd)] (9). 100 mg of 2 (0.122 mmol) were suspended in 15 ml DME and 
93 mg of 1,10-phenantroline-5,6-dione (phd, 1.25 eq.) were added. The suspension was heated to 60 °C 
for 3.5 h and stopped when the red suspension had become a deep red solution. The mixture was 
allowed to cool to RT and then filtered. The dark red solution was dried in vacuo leaving 9 as a dark red 
solid. The crude product was recrystallized from a CH2Cl2/hexane mixture. Yield: 60 mg, 81%. Anal. 
Calc. for C14H6Br2N2O4Re (612.2): C 27.47%, H 0.99%, N 4.58%. Found: C 28.11%, H 1.13%, N 
4.38%. I.r. (solid state, KBr, cm-1): νC O 1996, 1859. 
Synthesis of [ReBr2(CO)2(4,7-Mephen)] (10). 100 mg of 2 (0.122 mmol) were suspended in 15 ml 
DME and 26 mg (1.25 eq.) of 4,7-dimethyl-1,10-phenantroline (4,7-Mephen) were added. The 
suspension was heated to 60 °C for 3.5 h and stopped when the red suspension had become a deep red 
solution. The mixture was allowed to cool to RT and then filtered. The dark red solution was dried in 
vacuo leaving 10 as a dark red solid. The crude product was recrystallized from a CH2Cl2/hexane 
mixture. Yield: 70 mg, quantitative. Anal. Calc. for C16H12Br2N2O2Re (610.3): C 31.49%, H 1.98%, N 
4.59%. Found: C 31.67%, H 1.53%, N 4.76%. I.r. (solid state, KBr, cm-1): νC O 1997, 1844.  
Synthesis of [ReBr2(CO)2(2,2 -dipy-NH)] (11). 100 mg of 2 (0.122 mmol) were suspended in 15 ml 
DME and 21 mg (1.25 eq.) of 2,2 -dipyridylamine (2,2 -dipy-NH) were added. The suspension was 
stirred at RT for 12 h and then filtered. The light orange residue was identified as a mixture of unreacted 
starting materials and Et4NBr. The remaining solution was dried in vacuo leaving a dark yellow/green 
oil. This was dissolved in CHCl3 (1 ml) and hexane was slowly added. Compound 11 was then collected 
by filtration as a dark red solid. Yield: 42 mg, 60%. Anal. Calc. for C12H9Br2N3O2Re (573.2): C 25.14%, 
H 1.58%, N 7.33%. Found: C 24.89%, H 1.58%, N 7.25%. I.r. (solid state, KBr, cm-1): νC O 1992, 1837. 
Single crystals suitable for x-ray diffraction were grown by slow diffusion of ether into an acetone 
solution of the compound giving dark red crystals. 
 
Results and Discussion. 
Synthesis of Complexes. 
A summary of the reactions of 2 with different mono-, bi- and tridentate ligands is given in scheme 2. 
As we have previously shown, complex 2 reacts well with monodentate nitrogen containing aromatic 
ligands.1 Thus the reaction with N-methylimidazole (MeIm), 4-picoline (4-pic) or benzimidazole (BzIm) 
gave the corresponding cis-trans-[ReII(CO)2Br2L2] complex (3 with L = MeIm, 4 with L = BzIm, 5 with 
L = 4-pic). The direct substitution reaction of 2 with this type of ligands allowed to isolate 3, 4 and 5 in 
a short time and in good isolated yields (>50%). With the exception of 3, which was found to be 
hygroscopic and slowly decomposed over time, 4 and 5 appear indefinitely stable as solids under 
aerobic conditions.  
       
 
Scheme 2. Synthesis of ReII complexes evaluated in this study. All compounds were obtained via 
substitution reactions from the common cis-[ReII(CO)2Br4]2- (2) precursor. 
 
Complexes 3-5 are soluble in common organic solvents like methanol, CH2Cl2, acetonitrile or DMSO, 
and, even under aerobic conditions, were stable for days. X-ray quality crystals of 3, 4 and 5 could be 
grown from CH2Cl2 and hexane and the x-ray structures of these are given in figure 1. In all cases the 
ligands L substituted the two bromides trans to the CO’s giving [ReII(CO)2Br2L2] complexes with a cis-
trans-cis arrangement of the ligands. Since the cis arrangement of the two COs is the only structural 
compulsion, other isomers are expected as well but were not observed. We propose that the trans-
labilizing effect of the CO ligands may account for this selectivity.  
A common feature of the complexes 3-5 is the bending of the two trans bromides away from the CO’s 
with an average Br-Re-Br angle of 171.5°. Bond lengths and angles of 3 and 5 were found similar to the 
related imidazole and pyridine complexes cis-trans-[ReII(CO)2Br2(Im)2] (6) and cis-trans-
[ReII(CO)2Br2(py)2] (7) previously described.1 When reacted with other heterocyclic ligands like 
tetrahydrofuran or thiophene, 2 was always recovered unreacted indicating that, under similar 
experimental conditions, these ligands are not strong enough to replace the bound bromides even if 
present in large excess.  
While the MeIm and 4-pic ligands were mainly selected in order to provide data for comparison to the 
Im and py adducts 6 and 7, BzIm was also selected as a simple model for the interaction of 2 with 
purine bases. In 4 the two BzIm ligands are found in a head-to-tail (HT) conformation. Our previous 
results of the interaction of DNA bases with the fac-[ReI(CO)3(H2O)3]+ complex have shown that neither 
hydrogen bonding interactions nor steric factors are important in determining the orientation of the 
bases around the ReI core.44-48 Theoretical calculations indicated that the energy difference between 
rotamers is only ca. 5 Kcal/mol and we have shown that the different head-to-head (HH) or HT 
conformers observed in the solid state structures of the adducts are a result of packing effects.45 
Although any comments on a possible interaction of 2 with DNA is premature, we expect also the BzIm 
and other purine-type ligands to be able to rotate around cis-[Re(CO)2]2+ core. Thus, we suggest that HT 
conformer observed in the solid state structure of 4 is unlikely to be the predominant form in solution. 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1. ORTEP presentation of complexes 3 (A), 4 (B) and 5 (C). Selected bond lengths (Å) and 
angles (°) for 3 are: Re(1)-Br(1) 2.5301(5); Re(1)-Br(2) 2.5261(5); Re(1)-N(1) 2.183(3); Re(1)-N(3) 
2.172(3); Re(1)-C(1) 1.931(5); Re(1)-C(1) 1.930(4); Br(1)-Re(1)-Br(2) 171.802(16); for 4: Re(1)-Br(1) 
2.5194(4); Re(1)-N(1) 2.186(3); Re(1)-C(1) 1.920(4); Br(1)-Re(1)-Br(1_2) 168.67(2); and for 5: Re(1)-
Br(1) 2.5146(3); Re(1)-N(1) 2.207(2); Re(1)-C(1) 1.957(4); Br(1)-Re(1)-Br(1_2) 173.867(17).   
Ellipsoids are drawn at 50% probability. Hydrogen atoms are omitted for clarity. Atoms labeled with 
underscore ( _ ) are symmetry generated. 
 
A 
B 
C 
Reaction of 2 with bidentate bipyridine or phenantroline type ligands, proceeded smoothly with no 
reduction of the ReII center. Thus 4,4'-dimethyl-2,2'-bipyridine (4,4'-Mebipy),  1,10-phenantroline-5,6-
dione (phd),  4,7-dimethyl-1,10-phenantroline (4,7-Mephen) and 2,2 -dipyridylamine (2,2 -dipy-NH) 
gave the corresponding cis-trans-[ReII(CO)2Br2N∩N] complexes (8 with N∩N = 4,4'-Mebipy, 9 with 
N∩N = phd, 10 with N∩N = 4,7-Mephen and 11 with N∩N = 2,2 -dipy-NH; see scheme 2). 
 
Table 1. Spectroscopic and electrochemical properties of complexes 2-13. 
 
Complex νCO (cm-1)a E½, (mV)b λmax 
(nm)c 
[Re(CO)2Br4]2- (2) 1 1972, 1796 -120 412 
[Re(CO)2Br2(MeIm)2] (3) 1982, 1825 dec. 418 
[Re(CO)2Br2(BzIm)2] (4) 1992, 1833 -195 418 
[Re(CO)2Br2(4-pic)2] (5) 1992, 1830 -90 423 
[Re(CO)2Br2(Im)2] (6) 1 1988, 1826 dec. 418 
[Re(CO)2Br2(py)2] (7) 1 1990, 1825 -76 425 
[Re(CO)2Br2(4.4 -Mebipy)] (8) 1996, 1813 -104 421 
[Re(CO)2Br2(phd)] (9) 1996, 1859  428 
[Re(CO)2Br2(4.7-Mephen)] (10) 1997, 1844 -92 423 
[Re(CO)2Br2(2,2 -dipy-NH)] (11) 1992, 1837 -86 427 
[Re(CO)2Br2(bipy)] (12) 1 1989, 1837 -80 424 
[Re(CO)2Br2(phen)] (13) 1 1993, 1862 -74 426 
a KBr. b Potentials are reported vs. Ag/AgCl reference electrode in CH3OH with 0.1 M TBAPF6 as an 
electrolyte. All processes are one electron and refer to the ReII → ReI reduction. c in CH3OH 2, in 
CH2Cl2 all others.  
 
Complexes 8-11, isolated in good yield (>60%), are soluble in common organic solvents like methanol, 
CH2Cl2, acetonitrile or DMSO. They were found to be stable for days both as solids and in solution even 
under aerobic conditions. Complexes 8-11 show similar spectroscopic and electrochemical properties to 
the related cis-trans-[ReII(CO)2Br2(bipy)] (12) and cis-trans-[ReII(CO)2Br2(phen)] (13) previously 
published.1 These properties are listed in table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. ORTEP presentation of 8 (top) and 11. Selected bond lengths (Å) and angles (°) are for 8: 
Re(1)-Br(1) 2.5207(4); Re(1)-N(1) 2.169(3); Re(1)-C(1) 1.948(4); Br(1)-Re(1)-Br(1_2) 175.491(18); 
for 11: Re(1)-Br(1) 2.5074(18); Re(1)-Br(2) 2.5366(17); Re(1)-N(1) 2.200(8); Re(1)-C(1) 1.935(12); 
Br(1)-Re(1)-Br(2) 174.61(7); Ellipsoids are drawn at 50% probability. Hydrogen atoms are omitted for 
clarity. 
 
X-ray quality crystals of 8 and 11 could be grown from a CH2Cl2/hexane and an acetone/ether mixture 
respectively. The x-ray structures of 8 and 11 are given in figure 2. As expected, in the complexes the 
N∩N ligands were found trans to the CO’s and the two bromides bent away from the carbonyl groups 
forming an average angle of 175.1°. In 8 the 4,4'-Mebipy ligand is not flat but the two pyridines are 
twisted so as to form an  angle of ca. 15°. While such feature is not uncommon for bipyridine type 
ligands, a search of the CCDC has revealed that the only other monomeric rhenium complex showing 
such a severe twist of the bound pyridines is the cis-trans-[ReI(CO)2(PPh3)(POEt3)(4,4'-Mebipy)]+ 
recently reported by Ishitani.49 In 11 binding of 2,2 -dipy-NH occurs via the pyridine units. This feature 
makes complex 11 particularly interesting because derivatization of the bridging amine (e.g. via 
alkylation, or by appending a peptide vector) could offer new labeling strategies with ReII based 
complexes or help for a targeted delivery of CO-RMs. Crystallographic details are given in table 2. 
 
Table 2. Crystallographic data for compounds 3-5, 8 and 11.  
Compound 3 4 5 8 11 
Formula C10H12Br2N4O2Re C16H12Br2N4O2Re C14H14Br2N2O2Re C14H12Br2N2O2Re C12H9Br2N3O2Re 
FW 566.26 638.32 588.29 586.28 573.24 
T, K 183(2) 183(2) 183(2) 183(2) 183(2) 
space group C2/c C2/c Pcca C2/c Pnma 
crystal 
system 
monoclinic monoclinic orthorhombic monoclinic orthorhombic 
Z 8 4 4 4 4 
a, Å 30.1515(16) 10.6383(4) 13.33059(15) 6.50367(15) 7.8516(3) 
b, Å 7.62680(19) 12.4396(3) 8.38345(9) 18.6076(4) 14.3410(5) 
c, Å 15.1080(7) 13.7647(4) 15.52929(19) 13.4408(3) 12.8531(6) 
β, deg 119.758(7) 99.358(3) 90 101.791(2) 90 
V, Å3 3016.1(2) 1797.34(9) 1735.50(3) 1592.26(6) 1447.27(10) 
dcalc, g/cm3 2.494 2.359 2.252 2.446 2.631 
R1(wR2)a 0.0319 (0.0569) 0.0253 (0.0670) 0.0200 (0.0640) 0.0302 (0.0840) 0.0384, (0.0654) 
largest diff. 
peak / hole (e 
Å-3) 
1.639 and -0.894 1.170 and -0.842 0.848 and -1.208 1.122 and -1.403 2.852 and -1.043 
a [I>2sigma(I)] 
 
 CO Releasing Properties of cis-trans-[ReII(CO)2Br2L2]n Complexes. 
The carbon monoxide releasing properties of cis-trans-[ReII(CO)2Br2L2]n complexes were evaluated 
by the myoglobin assay (figure 3). This assay was shown to be a reliable method for assessing the 
amount and kinetic of CO liberation from CO-releasing molecules.5, 19, 21 In these experiments, an aliquot 
of a freshly prepared concentrated solution of the [ReII(CO)2Br2L2]n complex was added to a buffered 
solution of horse skeletal myoglobin (Mb), freshly reduced with excess sodium dithionite under N2. 
With the exception of 2 all complexes are insoluble in water. However, stock solutions of 2 in water 
were found to generate an inactive form of the complex due to the rapid CO release from this 
compound. Thus solutions of 2 were prepared in methanol while stock solutions of 3-13 were prepared 
in DMSO. The final methanol or DMSO content of the buffered aqueous solution never exceeded 0.5%. 
The conversion of Mb to carbon monoxide myoglobin (MbCO) was followed over time by measuring 
the changes in the absorption spectra of the Q band region of this protein at pH 7.4, 6.3 and 5.8 after 
addition of the ReII complex. The maximal absorption peak of Mb at 560 nm was rapidly converted over 
time to spectrum of MbCO, with two maximal absorption peaks at 540 and 578, respectively. A typical 
spectrum is shown in figure 3.  
 
 
 
 
 
 
 
Figure 3. A typical spectrum of conversion of deoxy-myoglobin (Mb) to carbon monoxide myoglobin 
(MbCO) by a cis-trans-[ReII(CO)2Br2L2]n complex. Here reproduced is the spectrum change of a 30 μM 
Mb solution after the addition of species 4 (30 μM, 25°C, 0.1 M phosphate buffer pH 7.4, spectra 
intervals = 5min).   
Only compounds bearing monodentate ligands (i.e. compounds 2-7) elicited the spectral changes 
associated with CO release. All other complexes bearing a N∩N type of ligand did not liberate CO. The 
amount of MbCO formed over time after addition of the ReII complex to the Mb solution was calculated 
according to the known extinction coefficients.19 The MbCO concentration was directly related to the 
equivalents of CO released from the compounds and these were plotted as a function of time. Figure 4 
shows the pH-dependent rate of CO release of different cis-trans-[ReII(CO)2Br2L2]n complexes. The 
half-lives (t1/2) of CO release from the ReII complexes at different pH’s were estimated from these 
graphs and are listed in table 3.  
 
Table 3. Half−lives (t1/2, min, 25 °C)a for the release of 1 equivalent of CO by cis-[Re(CO)2Br2L2]n 
complexes at different pH’s.b 
Complex c t1/2 at pH 5.8 t1/2 at pH 6.3 t1/2 at pH 7.4 
[Re(CO)2Br4]2- (2) 1.0 2.5 5.7 
[Re(CO)2Br2(MeIm)2] (3) 19.9 27.0 40.7 
[Re(CO)2Br2(BzIm)2] (4) 8.4 12.3 14.0 
[Re(CO)2Br2(4-pic)2] (5) 15.2 20.3 23.6 
[Re(CO)2Br2(Im)2] (6) 29.8 41.3 42.3 
[Re(CO)2Br2(py)2] (7) 9.7 10.2 17.2 
a Half-lives (t1/2) were estimated from the graphs shown in figure 4. b 0.1 M phosphate buffer. c 
Complexes 8-13 do not release CO. 
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Figure 4. The pH-dependent rate of CO release of different cis-trans-[ReII(CO)2Br2L2]n complexes. 
Conditions: 30 μM Mb and corresponding ReII species, 25°C, 0.1 M phosphate buffer pH 7.4( ), 6.3 
( ), 5.8 ( ).   
 
When the experiments were performed under conditions of a limiting amount of the metal complexes, 
taking into account the molar extinction coefficient of MbCO19, it was found that approximately 1 mol 
of CO was released per mole of the corresponding [ReII(CO)2Br2L2]n species. Thus only one CO ligand 
is liberated from the metal complexes 2-7. The CO detection via this assay proceeded as expected with 
three isosbestic points at 552, 567 and 587 nm clearly visible in the spectrum (see figure 3). As 
described above, changes in the spectrum are indicative of the conversion of Mb to MbCO.  
However, after full CO saturation of Mb the molar absorptivity in the Q band region of MbCO 
increased over time beyond the expected calculated value. All three isosbestic points were lost. There 
was no further spectral change in terms of the position of the maximal absorption peaks at 540 and 578, 
but only an apparent increase in their molar absorptivity. This was true for all [ReII(CO)2Br2L2]n species 
tested and for all pH’s. This type of spectral changes have been previously attributed to an increase in 
the turbidity of the solution as a result CO-RM precipitation.50 It is also possible that the apparent 
increase in the molar absorptivity in the Q band region of MbCO may be due to an interaction of the 
resulting Re complexes with the protein. This interaction might explain the increase in absorption 
intensity due to further lowering of MbCO symmetry.27 
The rate of CO loss from 2-7 was found to be pH-dependent with half lives (t1/2) under physiological 
conditions (pH 7.4) varying from ca. 6 (for 2) to 43 min (for 6, table 3). At lower pH values the time 
required to fully saturate Mb with CO liberated from the metal complexes gradually decreased. This was 
generally true for all compounds except for [Re(CO)2Br2(Im)2] (6) and [Re(CO)2Br2(py)2] (7) where 
only small difference were detected between pH 7.4 and 6.3 and between pH 6.3 and 5.8 respectively 
(table 3). The pH-dependent CO-cleavage of the cis-trans-[ReII(CO)2Br2L2]n species is not yet fully 
understood. It may be due to a cis-labilizing effect of potential π-donors such as H2O which could 
substitute the bound bromide ions. Also, as previously suggested,51 this type of pH-dependence may 
point to an associatively activated substitution mechanism. This is reasonable in light of the fact that all 
Re species investigated are 17e- complexes.  
Complex 2 was found to be the most rapid CO-releasing molecule (CO-RM) in all cases while the 
imidazole adducts the slowest. The overall order for the rate of CO release is: 2 > 4 ≈ 7 > 5 > 3 ≈ 6. At 
pH 7.4 and at 25 °C saturation of Mb with CO liberated from 2 was reached within 30 min (t1/2 = 5.7 
min). This value is comparable to that of the fac-[RuCl(glycinato)(CO)3] complex (CORM-3) whose t1/2 
at pH 7.4 and at 37 °C has been reported to be ca. 1 min.5, 21 
 
Protective Action of Selected cis-trans-[ReII(CO)2Br2L2]n Complexes Against “Ischemia-
Reperfusion” Stress of Cardiomyocyte.   
The fac-[RuCl(glycinato)(CO)3] complex (CORM-3) has been shown to protect cardiac cells against 
hypoxia-reoxygenation stress and ischemia-reperfusion injury.5  Ischemia refers to an absolute or 
relative shortage of the blood supply to an organ, resulting in a shortage of oxygen, glucose and other 
nutrients transported via the blood. In order to test if cis-trans-[ReII(CO)2Br2L2]n complexes also showed 
a protective action  against “ischemia-reperfusion” stress of cardiac cells, neonatal rat ventricular 
cardiomyocytes (NRCs) kept under simulated ischemic conditions (i.e. glucose-free medium, pH 6.0, 
1% O2, 5% CO2 and 94% N2 for 16 h) were treated with compounds 2, 5, 6 and 7 at the “onset of 
reperfusion” (i.e. at the onset of normoxic conditions, 5 mM glucose, pH 7.4, 20% O2). The ReII 
complexes were selected so as to encompass the widest range of t1/2 of CO release (see table 3) in order 
to understand if the rate of CO loss may represent a determining factors in our results. 
Under normoxic conditions (i.e. normal 20% O2 level) almost 100% of NRCs stayed alive either in 
the absence or in the presence of 30 µM of complexes 2, 6 and 7. However, complex 5 proved to be 
very toxic by killing over 90% of cells within 12 h of treatment. In a second protocol the toxicity of low 
pH and glucose omission was tested and the cells were incubated for 16 h in glucose-free well-
oxygenated medium at pH of 6.0. Thereafter “reperfusion” step was simulated by replacing the medium 
by that containing 5 mM glucose at pH of 7.4. As in the “ischemia-reprfusion” protocol ReII complexes 
were added immediately after the medium replacement and the incubation duration fixed to 12 h. 
Similar to that under normoxic conditions, cell viability was not affected by these manipulations, except 
for complex 5, which again lead to over 90% cell mortality (data not shown). Finally the cells were 
exposed to a simulated ischemia-reperfusion.  Ischemic condition was simulated by exposing the cells to 
glucose-free medium of pH 6.0 in hypoxic incubator (1% O2, 5% CO2 and 94% N2). After 16 h of 
“ischemia” the selected ReII complexes 2, 5, 6 and 7 at final concentration of 30 µM were administered 
into the cell culture medium as it was changed to high glucose well-oxygenated medium of pH 7.4, 
namely  at the “onset of reperfusion”. Their cytoprotective efficacy was tested 12 h after the 
administration. Exposure of cells to the "ischemia-reperfusion" procedure reduced cell viability to ~75% 
(i.e. 25% dead cells) in the absence of ReII complexes (control in figure 5). Addition of complex 2 
during “reperfusion” incresed cell survival by 67% (~9% dead cells) and complex 6 by 83% (~4% dead 
cells), while complexes 5 and 7 displayed no significant protective effect (see figure 5). 
 
 
 
 
 
 
 
 
 
Figure 5. Cytoprotective effects of selected cis-trans-[ReII(CO)2Br2L2]n complexes (30 μM) against 
“ischemia-reperfusion” stress of neonatal rat ventricular cardiomyocytes (NRCs) as described in the 
experimental section. Numbers on the abscissa refer to ReII complexes whose CO release half-lives are 
given in table 3. Controls were subjected to the “ischemia-reperfusion” procedure without addition of 
ReII complexes. Bars indicate the % of PI-positive (dead) cells. Asterisks indicate statistical 
significance: *) p < 0.035  and **) p < 0.005.  
Figure 6 shows representative histochemical staining of cardiac cell cultures under different 
conditions. Propidium iodide (PI) only enters cells whose plasma membrane is damaged (dead cells) 
and stains the nucleic DNA (false red color). Hoechst 33342 permeates all cells and stains DNA in 
nuclei and mitochondria in living and dead cells (false green color). Superimposed nuclear staining in 
the merged pictures appear in yellow (selected nuclei are indicated by white arrows). The first vertical 
row shows cells under normoxia (no dead cells visible). The second vertical row contains cells subjected 
to the "ischemia-reperfusion" protocol without ReII complex displying ca. 25% dead cells (control in 
figure 5). In the third row the number of dead cells was reduced by complex 6 added during the 
reperfusion phase. None of the compounds tested was able to reduce cell mortality when present in the 
culture during the hypoxic phase alone. Taken together, these findings indicated that the CO released 
from the ReII complexes attenuated the oxidative toxicity during reoxygenation but was unable to 
support cell survival under conditions of oxygen deprivation as CO further reduced O2 availability. 
Atomic absorption spectroscopy (AAS) measurements indicated that complexes 2, 6 and 7 did not 
enter the cells through the cell surface membrane during a 3 h incubation period (data not shown). 
Compound 5, on the contrary, was actively taken into the cells with the uptake rate of ~ 40 
µmol/(106cells*h). Rhenium concentration in the medium decreased to <7-8 µM after 2 h of exposure 
suggesting that the compound was accumulating in the cells against the gradient and/or rapidly 
metabolised. Of note, accumulation of complex 5 was not followed by an immediate 90% mortality 
suggesting that not the compound itself, but rather the product(s) of its metabolism (such as 4-
methylpyridine), were the cause of its elevated toxicity.  These findings indicate that the cytoprotective 
action exerted by 2 and 6 may be attributed to the extracellular release of CO while the high toxicity of 
complex 5 may be related to its membrane permeability and accumulation into the cells. Our results 
further suggest that the rate of CO release is not a determining factor for the protection of NRCs. Both 
complex 2 (t1/2 of CO loss = ca. 6 min) and 6 (t1/2 = ca. 43 min) protect cardiomyocytes in our “ischemia-
reperfusion” protocol. Compound 7 (t1/2 = ca. 17 min) displayed no significant protection while 5 (t1/2 = 
ca. 24 min) was toxic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Representative histochemical staining of cardiac cell cultures under different conditions. Top 
horizontal row, staining of nuclear DNA (red) of dead cells with propidium iodide (PI). Middle row, 
staining of DNA (green) in nuclei and mitochondria (additional stain uptake in cell bodies) of dead and 
live cells with Hoechst 33342. Bottom row, merged pictures with yellow nuclei where the two stains 
overlay (selected cases highlighted by white arrows). Normoxia, in the absence of "ischemia-
reperfusion" no dead cells were observed; "ischemia-reperfuson" protocol induced around 25% dead 
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cells; addition of ReII complex 6 significantly reduced the number of dead cells. Each picture measures 
830 µm in width and 650 µm in hight, yielding an area of 0.54 mm2. 
 
 
 
With regard to the cytoprotective effect, all synthesized ReII complexes contain two molecules of 
carbon monoxides (CO). The myoglobin assay indicated that all complexes tested released one CO per 
molecule within 2 hours albeit at different rates (see table 3). Given the fact that the tested complexes 
(with the exception of 5) remain outside the cells, it must be assumed that the released CO that is known 
to be lipid soluble, readily enters the cells to exert its biological function.51 Whether the second CO will 
be released later during the 12 h of reperfusion is not known at present. It could be that metabolic 
interactions in the medium leads to structural rearrangements entailing release of the second CO 
molecule with progressing time. Anyhow, the results clearly indicate that complex 6 with the slowest 
CO release rate (t1/2 = ca. 43 min) offers the most extensive protection as compared to the slower CO 
releasing complex 2. Complex 7 displays no protection and the most lipophilic complex 5, which enters 
the cells, seems to precipitate cell mortality (figure 5). It is possible that in these two cases toxic 
properties may compete and outweigh the beneficial effects of CO (pyridines are cytotoxic themselves). 
 
Conclusion. 
The CO releasing properties of a new class of CO-RMs of general formula cis-trans-[ReII(CO)2Br2L2]n 
(where L = monodentate ligand) have been described. Only complexes bearing monodentate ligands 
were found to liberate CO. The rate of CO loss of the ReII compounds was found to be pH-dependent 
with half lives under physiological conditions varying from ca. 6 to 43 min. This feature makes the 
complexes potentially useful for medicinal applications. Because the rate of CO release can be 
controlled by the appropriate choice of L, fine tuning of the coordination sphere of the cis-trans-
[ReII(CO)2Br2]0 core would in principle allow for the design of compounds with specific rates of CO 
loss. In turn this feature allows controlling the rate of CO release and the selection of specific complexes 
when specific concentrations of CO are required. Selected cis-trans-[ReII(CO)2Br2L2]n complexes were 
found to induce a protective action against “ischemia-reperfusion” stress of neonatal rat ventricular 
cardiomyocytes in culture. Our biological results appear to indicate that the rate of CO release might not 
be a determining factor for the protection of cardiomyocytes. However, the possibility of derivatizing 
the cis-trans-[ReII(CO)2Br2]0 core with water soluble and biologically compatible ligands while retaining 
the fundamental CO-releasing properties, makes this class of CO-RMs unique in the field. Taken 
together, application of CO could open new therapeutic strategies for preventing pathologic 
developments in cardiovascular disease. However, due to its high affinity to the various heme proteins 
CO is also one of the most toxic substances, particularly when exogenously administered. Furthermore, 
potential treatment doses require careful evaluation and monitoring in order to avoid toxic side effects. 
The mechanism by which the cis-trans-[ReII(CO)2Br2L2]n (where L = monodentate ligand) species 
release CO is currently being investigated and efforts are directed towards the development of 
biocompatible CO releasing compounds coupled to water soluble scaffold moieties. 
 
Acknowledgements 
The Swiss National Science Foundation (Ambizione PZ00P2_121989/1 and Grant# 310030_124970/1) 
is gratefully acknowledged for financial support. We thank Nikolay Bogdanov (Institute of Veterinary 
Physiology) for his assistance in the isolation of the neonatal rat cardiomyocytes. 
References.  
1. Zobi, F.; Kromer, L.; Spingler, B.; Alberto, R., Inorg. Chem. 2009, 48, 8965-8970. 
2. Wu, L.; Wang, R., Pharmacol. Rev. 2005, 57, 585-630. 
3. Otterbein, L. E.; Bach, F. H.; Alam, J.; Soares, M.; Lu, H. T.; Wysk, M.; Davis, R. J.; Flavell, R. 
A.; Choi, A. M. K., Nature Med. 2000, 6, 422-428. 
4. Otterbein, L. E.; Choi, A. M. K., Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 279, L1029-
L1037. 
5. Clark, J. E.; Naughton, P.; Shurey, S.; Green, C. J.; Johnson, T. R.; Mann, B. E.; Foresti, R.; 
Motterlini, R., Circ. Res. 2003, 93, e2-8. 
6. Grilli, A.; De Lutiis, M. A.; Patruno, A.; Speranza, L.; Gizzi, F.; Taccardi, A. A.; Di Napoli, P.; 
De Caterina, R.; Conti, P.; Felaco, M., Ann. Clin. Lab. Sci. 2003, 33, 208-215. 
7. Guo, Y.; Stein, A. B.; Wu, W. J.; Tan, W.; Zhu, X.; Li, Q. H.; Dawn, B.; Motterlini, R.; Bolli, 
R., Am. J. Physiol. Heart Circ. Physiol. 2004, 286, H1649-1653. 
8. Liu, H.; Song, D.; Lee, S. S., Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280, G68-74. 
9. McGrath, J. J.; Smith, D. L., Proc. Soc. Exp. Biol. Med. 1984, 177, 132-136. 
10. Otterbein, L. E.; Zuckerbraun, B. S.; Haga, M.; Liu, F.; Song, R. P.; Usheva, A.; Stachulak, C.; 
Bodyak, N.; Smith, R. N.; Csizmadia, E.; Tyagi, S.; Akamatsu, Y.; Flavell, R. J.; Billiar, T. R.; Tzeng, 
E.; Bach, F. H.; Choi, A. M. K.; Soares, M. P., Nature Med. 2003, 9, 183-190. 
11. Mancuso, C.; KostoglouAthanassiou, I.; Forsling, M. L.; Grossman, A. B.; Preziosi, P.; Navarra, 
P.; Minotti, G., Mol. Brain Res. 1997, 50, 267-276. 
12. Mancuso, C.; Pistritto, G.; Tringali, G.; Grossman, A. B.; Preziosi, P.; Navarra, P., Mol. Brain 
Res. 1997, 45, 294-300. 
13. Snyder, S. H.; Jaffrey, S. R.; Zakhary, R., Brain Res. Rev. 1998, 26, 167-175. 
14. Takahashi, J. S.; Hong, H. K.; Ko, C. H.; McDearmon, E. L., Nature Rev. Gen. 2008, 9, 764-
775. 
15. Dioum, E. M.; Rutter, J.; Tuckerman, J. R.; Gonzalez, G.; Gilles-Gonzalez, M. A.; McKnight, S. 
L., Science 2002, 298, 2385-2387. 
16. Foresti, R.; Bani-Hani, M. G.; Motterlini, R., Intensive Care Med. 2008, 34, 649-658. 
17. Sawle, P.; Hammad, J.; Fairlamb, I. J.; Moulton, B.; O'Brien, C. T.; Lynam, J. M.; Duhme-Klair, 
A. K.; Foresti, R.; Motterlini, R., J. Pharmacol. Exp. Ther. 2006, 318, 403-410. 
18. Varadi, J.; Lekli, I.; Juhasz, B.; Bacskay, I.; Szabo, G.; Gesztelyi, R.; Szendrei, L.; Varga, E.; 
Bak, I.; Foresti, R.; Motterlini, R.; Tosaki, A., Life Sci. 2007, 80, 1619-1626. 
19. Motterlini, R.; Clark, J. E.; Foresti, R.; Sarathchandra, P.; Mann, B. E.; Green, C. J., Circ. Res. 
2002, 90, E17-24. 
20. Motterlini, R.; Mann, B. E.; Foresti, R., Expert. Opin. Investig. Drugs 2005, 14, 1305-1318. 
21. Motterlini, R.; Mann, B. E.; Johnson, T. R.; Clark, J. E.; Foresti, R.; Green, C. J., Curr. Pharm. 
Des. 2003, 9, 2525-2539. 
22. Motterlini, R.; Sawle, P.; Hammad, J.; Bains, S.; Alberto, R.; Foresti, R.; Green, C. J., FASEB J. 
2005, 19, 284-286. 
23. Loennechen, J. P.; Nilsen, O. G.; Arbo, I.; Aadahl, P.; Nilsen, T.; Waldum, H. L.; Sandvik, A. 
K.; Ellingsen, O., Toxicol. Appl. Pharmacol. 2002, 178, 8-14. 
24. Loennechen, J. P.; Beisvag, V.; Arbo, I.; Waldum, H. L.; Sandvik, A. K.; Knardahl, S.; 
Ellingsen, O., Pharmacol. Toxicol. 1999, 85, 192-197. 
25. Fairlamb, I. J. S.; Duhme-Klair, A. K.; Lynam, J. M.; Moulton, B. E.; O'Brien, C. T.; Sawle, P.; 
Hammad, J.; Motterlini, R., Bioorg. Med. Chem. Lett. 2006, 16, 995-998. 
26. Sawle, P.; Hammad, J.; Fairlamb, I. J. S.; Moulton, B.; O'Brien, C. T.; Lynam, J. M.; Duhme-
Klair, A. K.; Foresti, R.; Motterlini, R., J .Pharmacol. Exp. Ther. 2006, 318, 403-410. 
27. Atkin, A. J.; Williams, S.; Sawle, P.; Motterlini, R.; Lynam, J. M.; Fairlamb, I. J. S., Dalton 
Trans. 2009, 3653-3656. 
28. Fairlamb, I. J. S.; Lynam, J. M.; Moulton, B. E.; Taylor, I. E.; Duhme-Klair, A. K.; Sawle, P.; 
Motterlini, R., Dalton Trans. 2007, 3603-3605. 
29. Zhang, W. Q.; Atkin, A. J.; Thatcher, R. J.; Whitwood, A. C.; Fairlamb, I. J. S.; Lynam, J. M., 
Dalton Trans. 2009, 4351-4358. 
30. Niesel, J.; Pinto, A.; N'Dongo, H. W. P.; Merz, K.; Ott, I.; Gust, R.; Schatzschneider, U., Chem. 
Commun. 2008, 1798-1800. 
31. Pfeiffer, H.; Rojas, A.; Niesel, J.; Schatzschneider, U., Dalton Trans. 2009, 4292-4298. 
32. Desmard, M.; Davidge, K. S.; Bouvet, O.; Morin, D.; Roux, D.; Foresti, R.; Ricard, J. D.; 
Denamur, E.; Poole, R. K.; Montravers, P.; Motterlini, R.; Boczkowski, J., FASEB J. 2008, 23, 1-9. 
33. Foresti, R.; Hammad, J.; Clark, J. E.; Johnson, T. R.; Mann, B. E.; Friebe, A.; Green, C. J.; 
Motterlini, R., Br. J. Pharmacol. 2004, 142, 453-460. 
34. Johnson, T. R.; Mann, B. E.; Teasdale, I. P.; Adams, H.; Foresti, R.; Green, C. J.; Motterlini, R., 
Dalton Trans. 2007, 1500-1508. 
35. Pfeiffer, H.; Rojas, A.; Niesel, J.; Schatzschneider, U., Dalton Trans. 2009, (Advance Article). 
36. Kunz, P. C.; Huber, W.; Rojas, A.; Schatzschneider, U.; Spingler, B., Eur. J. Inorg. Chem. 2009, 
5358-5366. 
37. Alberto, R.; Egli, A.; Abram, U.; Hegetschweiler, K.; Gramlich, V.; Schubiger, P. A., J. Chem. 
Soc. Dalton Trans. 1994, 2815-2820. 
38. Abram, U.; Hubener, R.; Alberto, R.; Schibli, R., Z. Anorg. Allg. Chem. 1996, 622, 813-818. 
39. Oxford Diffraction Ltd. CrysAlisPro Software system, 171.32; Oxford, UK, 2007. 
40. Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, G. L.; Giacovazzo, C.; Guagliardi, A.; 
Moliterni, A. G. G.; Polidori, G.; Spagna, R., J. Appl. Cryst. 1999, 32, 115-119. 
41. Sheldrick, G. M., Acta Cryst. 2008, A64, 112-122. 
42. Spek, A. L., J. Appl. Cryst. 2003, 36, 7-13. 
43. Schafer, B. W.; Perriard, J. C., J. Cell Biol. 1988, 106, 1161-1170. 
44. Spingler, B.; Zobi, F.; Antoni, P. M.; Medina-Molner, A.; Alberto, R., Chimia 2005, 59, 826-
831. 
45. Zobi, F.; Blacque, O.; Schmalle, H. W.; Spingler, B.; Alberto, R., Inorg. Chem. 2004, 43, 2087-
2096. 
46. Zobi, F.; Blacque, O.; Sigel, R. K. O.; Alberto, R., Inorg. Chem. 2007, 46, 10458-10460. 
47. Zobi, F.; Spingler, B.; Alberto, R., Chembiochem 2005, 6, 1397-1405. 
48. Zobi, F.; Spingler, B.; Fox, T.; Alberto, R., Inorg. Chem. 2003, 42, 2818-2820. 
49. Koike, K.; Tanabe, J.; Toyama, S.; Tsubaki, H.; Sakamoto, K.; Westwell, J. R.; Johnson, F. P. 
A.; Hori, H.; Saitoh, H.; Ishitani, O., Inorg. Chem. 2000, 39, 2777-2783. 
50. Scapens, D.; Adams, H.; Johnson, T. R.; Mann, B. E.; Sawle, P.; Aqil, R.; Perrior, T.; Motterlini, 
R., Dalton Trans. 2007, 4962-4973. 
51. Alberto, R.; Motterlini, R., Dalton Trans. 2007, 1651-1660. 
 
 
TOC: Graphical entry 
 
The carbon monoxide (CO) releasing properties of a series of ReII-based complexes of general formula cis-trans-[ReII(CO)2Br2L2]n  (where L = 
monodentate ligand) are described. It is shown that the rate of CO loss from the cis-trans-[ReII(CO)2Br2]0 core can be easily controlled by varying the 
coordinated L. Selected cis-trans-[ReII(CO)2Br2L2]n complexes induce a protective action against “ischemia-reperfusion” stress of neonatal rat ventricular 
cardiomyocytes (NRCs) in culture. 
 
 
